Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

Rapid Technology Identifies Cancer Gene Status

By Labmedica International staff writers
Posted on 05 Mar 2013
Print article
A fluorescence in situ hybridization (FISH) assay will reduce the turnaround time for cancer evaluation from two days to three and a half hours.

This technology will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments.

Dako, an Agilent Technologies Company (Carpinteria, CA, USA) has introduced instant quality in situ hybridization (IQISH) technology in the United States of America. The HER2 IQFISH pharmDx test is a FISH assay, is the first product approved by the US Food and Drug Administration (Silver Spring, MD, USA) that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry.

The human epidermal growth factor receptor 2 (HER2) protein is encoded by gene called HER2, which promotes the growth of cells. In about one of every five breast cancers, the cancer cells make an excess of HER2 due to a HER2 gene mutation. The HER2 IQFISH pharmDx assay can support laboratories in identifying HER2 gene status with great accuracy and now, speed. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. As they are also less responsive to hormone treatment, medical treatments that specifically target HER2, for example trastuzumab, are often considered.

The IQFISH technology is also nontoxic, as it replaces a hazardous formamide buffer with a safer ethylene carbonate, contributing to a healthier work environment in the pathology laboratory. Lars Holmkvist, the CEO of Dako, said, "Every second counts when waiting for test results that will indicate how to treat your cancer most effectively. Dako is extremely proud to get the FDA's approval to introduce this offering to our US customers."

Kenneth J. Bloom, MD, FCAP, chief medical officer, Clarient Diagnostic Services Inc (Aliso Viejo, CA, USA) said, "HER2 IQFISH pharmDx will provide more timely results, allowing us to incorporate FISH analysis into our routine workflow as easily as immunohistochemistry.” HER2 IQFISH pharmDx has been sold in Europe and countries working with CE labeling, the mark of compliance with relevant European regulations, since February 2012.

Related Links:

Dako
US Food and Drug Administration
Clarient Diagnostic Services Inc.



Print article
Micromedic Technologies

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.